RayzeBio and Neumora Therapeutics have successfully entered public markets, with both firms offering multiple drug candidates in clinical trials. RayzeBio’s IPO, the larger of the two, raised $311 million. The company targets radiation cancer therapies and has a lead program, RYZ101, for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Neumora raised $250 million for its ongoing pivotal testing of a novel major depressive disorder drug.
Cohesity and Normalyze have partnered to provide an integrated cyber recovery and ransomware protection solution with data security posture management capabilities. Aimed at discovering, classifying,